Sichuan Biokin Stock Hits Day High with Strong Intraday Performance

Sichuan Biokin Pharmaceutical Co., Ltd. has experienced a notable uptick in its stock performance, gaining 5.3% on June 10, 2026. The stock reached an intraday high of CNY 223.23, showcasing significant activity amid a broader market context where the China Shanghai Composite index declined by 0.42% on the same day. In terms of performance metrics, Sichuan Biokin has shown a 3.7% increase over the past week, contrasting with a 2.22% drop in the Shanghai Composite. However, the company has faced challenges over a longer timeframe, with a 17.22% decrease in the past month and a substantial 34.96% decline over the past year. Year-to-date, the stock is down 31.92%, while it has demonstrated a remarkable 179.38% increase over the past three years. Despite the recent gains, the company has reported negative results for the last four consecutive quarters, with net sales declining by 63.52% and a net profit loss of CNY 500.37 million. The operating cash flow has also reached a low of CNY -2,331.46 million, indicating ongoing financial pressures.